Clinical Trial Update: Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a four-drug combination (venetoclax, cladribine, low-dose cytarabine, and azacitidine) for previously untreated acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Cladribine (cladribine)
• Cytarabine (Low-Dose) (cytarabine)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING